Cardiovascular risk in diabetes can be reduced using hormones, claims study

e363d334-2094-4d09-a3e6-3fd2b440b877articleimage.jpg

04 Dec 2017 --- Scientists at Joslin Diabetes Center in the US have taken another step toward solving a long-standing puzzle about heart health in Type 2 diabetes, with a finding that eventually may point towards more personalized patient care. Genetic analysis has linked the hormone known as glucagon-like peptide 1 (GLP-1) with cardiovascular mortality risks.

People with Type 2 diabetes, who are at least twice as likely to develop cardiovascular disease (CVD) as people without the condition, can generally reduce their risks by carefully controlling their glycemic (blood glucose) levels.

However, back in 2008, the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial made a paradoxical finding, says Alessandro Doria, M.D., Ph.D., M.P.H., a senior investigator in Joslin's Section on Genetics and Epidemiology. Among people with diabetes and high risk of CVD, it found that those who achieved extremely tight glycemic control showed higher risks of fatal heart attacks than those who did not, he says.

Last year, Doria and his colleagues made progress toward explaining this surprising discovery by identifying two genetic variants associated with a threefold increase in CVD specifically among patients in ACCORD who underwent intensive glycemic control.

GLP-1 holds key to genetic markers
Now in a paper published in Diabetes Care, the Joslin team has linked one of these genetic markers with levels of the hormone GLP-1, says Doria, senior author on the paper and an Associate Professor of Medicine at Harvard Medical School.

ACCORD participants who carried the variant associated with increased cardiovascular mortality showed a significant drop in fasting levels of GLP-1 during 12 months of intensive glycemic control, he says. GLP-1 levels were instead stable or increased among patients who did not carry that variant.

The Joslin team began its analysis by measuring 65 biomarker molecules in the blood among 351 people in ACCORD. The researchers then looked for an association between these biomarkers and the previously discovered genetic variants for CVD in the two arms of the study – one arm with intense glycemic control and the other arm with standard glycemic control. 

The most common measurement for glycemic control is a “hemoglobin A1C” or HbA1C test, which reflects average blood glucose levels over several months. Those in the trial's intensive-control group sought to reduce their HbA1C levels below 6 percent, while those following standard guidelines aimed for HbA1C levels below 8 percent.

While the link between higher risks of fatal heart attacks and lower GLP-1 levels after 12 months of intensive glycemic control was unexpected, it fitted in with what is known about the hormone.

“GLP-1 is produced by intestinal cells, and its main action is to stimulate insulin secretion from beta cells, but the hormone also has a beneficial effect on the heart and blood vessels that is independent from its action on insulin secretion,” says Doria.

The US Food & Drug Administration has approved several GLP-1 “agonist” drugs (injectable GLP-1-like molecules) for people with Type 2 diabetes, Doria says. In addition to lowering blood glucose, these drugs have been shown to improve cardiovascular health of diabetic patients. An earlier class of drugs known as DPP4 inhibitors, given orally, aims to provide similar effects by preserving the hormone in the bloodstream.

If the latest Joslin study is confirmed by other research, it will suggest that people with diabetes eventually might be tested for the genetic risk marker associated with lower GLP-1 levels. This testing could be done relatively inexpensively, Doria says, and patients who carry this marker might be particularly good candidates for using GLP-1 drugs to improve their glycemic control.

Doria and his co-workers will follow up on their work with experiments in cells that help them understand how the genetic variant affects GLP-1 production.

Additionally, the scientists will analyze other ACCORD data to pursue other methods that might help to personalize heart health in Type 2 diabetes. “The trial itself was concluded in 2009, but researchers continue to mine its data, which shows the deep benefits of carefully collected data sets and samples,” Doria says.

Related Articles

Business News

Weight management program can put Type 2 diabetes into remission finds Lancet study

06 Dec 2017 --- Type 2 diabetes can be reversed following an intensive weight management program, according to a randomized trial in adults who have had the condition for up to six years, published in The Lancet. The findings lend support to the widespread use of this type of intervention in the routine care of Type 2 diabetes across health services.

Nutrition & Health News

Harmful effects of overweight have been underestimated, notes BMI study

04 Dec 2017 --- The harmful effects of being overweight have been underestimated, according to a new study that analyzed body mass index (BMI), health and mortality data in around 60,000 parents and their children to establish how obesity actually influences the risk of death. The University of Bristol, UK study is published in the International Journal of Epidemiology.

Business News

Scientists find natural mimetics of anti-cancer and anti-aging drugs

04 Dec 2017 --- Researchers from the Biogerontology Research Foundation in the UK, Insilico Medicine, Life Extension and other institutions have announced the publication of a landmark study in the journal Aging on the identification of natural mimetics of metformin and rapamycin.

Nutrition & Health News

Studies shed light on negative effects of excess weight on arthritis patients

04 Dec 2017 --- New research provides insights on the potential negative effects of overweight and obesity on the health of individuals with rheumatoid arthritis (RA). A study published in Arthritis Care & Research examines how overweight and obesity may negatively affect the likelihood of achieving remission in early RA. A separate study in Arthritis & Rheumatology focuses on weight change in early RA and patients’ subsequent risk of early death.

Nutrition & Health News

US Global Health Committee report on heart disease burden: prioritize noncommunicable diseases

01 Dec 2017 --- The US must prioritize its health resources toward detecting and treating noncommunicable diseases, such as cardiovascular disease, while maintaining and expanding prevention and eradication of infectious diseases on a global scale. This is according to a report modified from US global health recommendations from the National Academies of Sciences, Engineering and Medicine (previously the Institute of Medicine) published in the Journal of the American College of Cardiology.

More Articles
URL : http://www.nutritioninsight.com:80/news/cardiovascular-risk-in-diabetes-can-be-reduced-using-hormones-claims-study.html